文献速递肝病消化道肿瘤与早癌

免疫标志物与HBV/HCV感染者肝细胞癌风险

Immunologic markers and risk of hepatocellular carcinoma in hepatitis B virus- and hepatitis C virus-infected individuals.
PubMed 文献 · Aliment Pharmacol Ther · 2021-07-19

基于台湾REVEAL-HBV和REVEAL-HCV队列,比较HCC病例与肝硬化及非肝硬化对照的102种血浆标志物。ICAM-1水平升高与两队列HCC风险增加相关,并新发现CXCL11、HGF正相关及CFHR5、SCF负相关。

要点

  • ICAM-1水平升高与HBV和HCV感染者HCC风险增加相关
  • CXCL11和HGF与HCC风险正相关,CFHR5和SCF负相关
  • 免疫过程在HBV/HCV相关HCC中可能起重要作用

核心结论

  • confirmed ICAM-1 association and identified 4 additional proteins associated with HBV- and HCV-related HCC.

研究设计与样本

  • REVEAL-HBV队列纳入175例HCC、117例仅肝硬化、165例非肝硬化对照。
  • REVEAL-HCV队列纳入94例HCC、68例仅肝硬化、100例非肝硬化对照。
  • 采用多项逻辑回归比较诊断前血浆102种标志物水平。

主要发现

  • 两队列中ICAM-1水平升高与HCC风险增加相关(P-trend分别为0.02和0.001)。
  • CXCL11和HGF与非肝硬化对照相比与HCC风险正相关(HCV中HGF最高OR Q4 vs Q1为4.55)。
  • CFHR5和SCF与非肝硬化对照相比与HCC风险负相关(HCV中SCF最高OR Q4 vs Q1为0.14)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinical and experimental studies suggest immunologic proteins contribute to hepatocellular carcinoma (HCC) development. AIM: To evaluate circulating immunologic markers and HCC risk. METHODS: From a Taiwanese cohort of chronically hepatitis B virus (HBV)-infected individuals followed over time (REVEAL-HBV), we sampled 175 who developed HCC, 117 cirrhosis only, and 165 non-cirrhotic controls. From a similar Taiwanese cohort of chronically hepatitis C virus (HCV)-infected individuals (REVEAL-HCV), we included 94 individuals who developed HCC, 68 cirrhosis only and 100 non-cirrhotic controls. We compared pre-diagnostic plasma levels of 102 markers in HCC cases to non-cirrhotic and cirrhotic controls using polytomous logistic regression. A priori markers included insulin-like growth factor binding protein-3 (IGFBP-3), intercellular adhesion molecule 1 (ICAM-1) and interleukin 6 (IL-6). P-values for other markers were corrected for multiple testing (false discovery rate = 10%). RESULTS: In both REVEAL-HBV and REVEAL-HCV, increasing levels of ICAM-1 were associated with increased risk of HCC compared to non-cirrhotic controls (P-trend 0.02 and 0.001, respectively). In both REVEAL-HBV and REVEAL-HCV, two novel markers [C-X-C motif chemokine 11 (CXCL11) and hepatocyte growth factor (HGF)] were positively associated [strongest odds ratioquartile 4 versus 1 (OR) 4.55 for HGF in HCV], while two [complement factor H related 5 (CFHR5) and stem cell factor (SCF)] were negatively associated (strongest ORQ4vQ1 0.14 for SCF in HCV) with development of HCC compared to non-cirrhotic controls. CONCLUSIONS: We confirmed the association for ICAM-1 and identified 4 additional proteins associated with HBV- and HCV-related HCC. These findings highlight the importance of immunologic processes in HBV- and HCV-related HCC.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Koshiol J, Argirion I, Liu Z, et al. Immunologic markers and risk of hepatocellular carcinoma in hepatitis B virus- and hepatitis C virus-infected individuals. Aliment Pharmacol Ther. 2021. PMID: 34286851. doi:10.1111/apt.16524

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。